NovoCure Operating Expenses Growth & History (NVCR)
NovoCure's operating expenses was $642.3M for fiscal 2025.
View full NovoCure company overviewNovoCure annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $642.3M | $3.7M | +0.59% |
| 2024 | 2024-12-31 | $638.5M | $24.6M | +4.01% |
| 2023 | 2023-12-31 | $613.9M | $101.4M | +19.79% |
| 2022 | 2022-12-31 | $512.5M | $48.0M | +10.34% |
| 2021 | 2021-12-31 | $464.5M | $107.0M | +29.94% |
| 2020 | 2020-12-31 | $357.5M | $93.8M | +35.60% |
| 2019 | 2019-12-31 | $263.6M | $61.9M | +30.71% |
| 2018 | 2018-12-31 | $201.7M | $40.9M | +25.47% |
| 2017 | 2017-12-31 | $160.7M | $8.8M | +5.81% |
| 2016 | 2016-12-31 | $151.9M | $35.5M | +30.44% |
| 2015 | 2015-12-31 | $116.5M | $30.9M | +36.05% |
| 2014 | 2014-12-31 | $85.6M | $17.8M | +26.26% |
| 2013 | 2013-12-31 | $67.8M | — | — |
NovoCure quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $153.0M | −$3.8M | −2.43% |
| Q1 2026 | 2026-03-31 | $202.5M | $48.2M | +31.24% |
| Q4 2025 | 2025-12-31 | $172.6M | −$18.5M | −9.69% |
| Q3 2025 | 2025-09-30 | $158.5M | $6.7M | +4.40% |
| Q2 2025 | 2025-06-30 | $156.9M | $7.6M | +5.07% |
| Q1 2025 | 2025-03-31 | $154.3M | $8.0M | +5.47% |
| Q4 2024 | 2024-12-31 | $191.1M | $38.2M | +24.95% |
| Q3 2024 | 2024-09-30 | $151.8M | −$1.7M | −1.08% |
| Q2 2024 | 2024-06-30 | $149.3M | −$5.4M | −3.50% |
| Q1 2024 | 2024-03-31 | $146.3M | −$6.5M | −4.24% |
| Q4 2023 | 2023-12-31 | $152.9M | $10.4M | +7.31% |
| Q3 2023 | 2023-09-30 | $153.5M | $27.6M | +21.94% |
| Q2 2023 | 2023-06-30 | $154.7M | $21.2M | +15.88% |
| Q1 2023 | 2023-03-31 | $152.8M | $42.2M | +38.14% |
| Q4 2022 | 2022-12-31 | $142.5M | $15.6M | +12.29% |
| Q3 2022 | 2022-09-30 | $125.9M | $13.9M | +12.42% |
| Q2 2022 | 2022-06-30 | $133.5M | $16.3M | +13.89% |
| Q1 2022 | 2022-03-31 | $110.6M | $2.2M | +2.06% |
| Q4 2021 | 2021-12-31 | $126.9M | $23.2M | +22.37% |
| Q3 2021 | 2021-09-30 | $112.0M | $22.7M | +25.45% |
| Q2 2021 | 2021-06-30 | $117.2M | $33.4M | +39.90% |
| Q1 2021 | 2021-03-31 | $108.4M | $27.7M | +34.30% |
| Q4 2020 | 2020-12-31 | $103.7M | $29.4M | +39.61% |
| Q3 2020 | 2020-09-30 | $89.2M | $23.9M | +36.65% |
| Q2 2020 | 2020-06-30 | $83.8M | $19.4M | +30.08% |
| Q1 2020 | 2020-03-31 | $80.7M | $21.1M | +35.39% |
| Q4 2019 | 2019-12-31 | $74.3M | $19.0M | +34.32% |
| Q3 2019 | 2019-09-30 | $65.3M | $14.3M | +27.92% |
| Q2 2019 | 2019-06-30 | $64.4M | $15.6M | +32.08% |
| Q1 2019 | 2019-03-31 | $59.6M | $13.0M | +28.02% |
| Q4 2018 | 2018-12-31 | $55.3M | $12.8M | +30.06% |
| Q3 2018 | 2018-09-30 | $51.1M | $10.2M | +24.90% |
| Q2 2018 | 2018-06-30 | $48.8M | $8.0M | +19.66% |
| Q1 2018 | 2018-03-31 | $46.6M | $10.0M | +27.26% |
| Q4 2017 | 2017-12-31 | $42.5M | $5.4M | +14.49% |
| Q3 2017 | 2017-09-30 | $40.9M | $2.1M | +5.29% |
| Q2 2017 | 2017-06-30 | $40.8M | $1.8M | +4.64% |
| Q1 2017 | 2017-03-31 | $36.6M | −$420,000 | −1.13% |
| Q4 2016 | 2016-12-31 | $37.1M | $460,000 | +1.25% |
| Q3 2016 | 2016-09-30 | $38.8M | $11.3M | +41.00% |
| Q2 2016 | 2016-06-30 | $38.9M | $9.9M | +34.30% |
| Q1 2016 | 2016-03-31 | $37.0M | $13.8M | +59.13% |
| Q4 2015 | 2015-12-31 | $36.7M | — | — |
| Q3 2015 | 2015-09-30 | $27.5M | $7.8M | +39.81% |
| Q2 2015 | 2015-06-30 | $29.0M | — | — |
| Q1 2015 | 2015-03-31 | $23.3M | — | — |
| Q3 2014 | 2014-09-30 | $19.7M | — | — |
NovoCure operating expenses trends
Over the last five fiscal years, NovoCure's operating expenses increased from $357.5M to $642.3M, a change of $284.8M. The latest reported quarter, Q2 2026, shows $153.0M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗